GovWire

Cimalgex 8 mg / 30 mg / 80 mg Chewable Tablets for Dogs – SPC change

Veterinary Medicines Directorate

June 20
14:12 2024

Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPC) for Cimalgex 8 mg / 30 mg / 80 mg Chewable Tablets for Dogs has been updated:

  • Polyuria and/or polydipsia may be observed on rare occasions and severe gastrointestinal and renal adverse events may be fatal.

All updates to SPCs other than template changes, are published in the medicine updates section of VMD Connect.

Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.

No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) o

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: